Functional compounds of ginseng and ginseng-containing medicine for treating cardiovascular diseases

Lanchun Liu, Jun Hu, Qiyuan Mao, Chao Liu, Haoqiang He, Xiaoshan Hui, Guang Yang, Peirong Qu, Wenjing Lian, Lian Duan, Yan Dong, Juhua Pan, Yongmei Liu, Qingyong He, Jun Li, Jie Wang, Lanchun Liu, Jun Hu, Qiyuan Mao, Chao Liu, Haoqiang He, Xiaoshan Hui, Guang Yang, Peirong Qu, Wenjing Lian, Lian Duan, Yan Dong, Juhua Pan, Yongmei Liu, Qingyong He, Jun Li, Jie Wang

Abstract

Ginseng (Panax ginseng C.A.Mey.) is the dry root and rhizome of the Araliaceae ginseng plant. It has always been used as a tonic in China for strengthening the body. Cardiovascular disease is still the main cause of death in the world. Some studies have shown that the functional components of ginseng can regulate the pathological process of various cardiovascular diseases through different mechanisms, and its formulation also plays an irreplaceable role in the clinical treatment of cardiovascular diseases. Therefore, this paper elaborates the current pharmacological effects of ginseng functional components in treating cardiovascular diseases, summarizes the adverse reactions of ginseng, and sorts out the Chinese patent medicines containing ginseng formula which can treat cardiovascular diseases.

Keywords: cardiovascular disease; functional components; ginsenoside; herbal medicine; panax ginseng.

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2022 Liu, Hu, Mao, Liu, He, Hui, Yang, Qu, Lian, Duan, Dong, Pan, Liu, He, Li and Wang.

Figures

FIGURE 1
FIGURE 1
Ginsenosides in treating cardiovascular diseases.

References

    1. Ahluwalia N., Andreeva V. A., Kesse-Guyot E., Hercberg S. (2013). Dietary patterns, inflammation and the metabolic syndrome. Diabetes Metab. 39 (2), 99–110. 10.1016/j.diabet.2012.08.007
    1. An G. H., Geng X. F., Ji M. C. (2003). Interaction between hypoglycemic drugs and other drugs. Chin. J. Clin. Pharmacol. (01), 67–70+74. 10.13699/j.cnki.1001-6821.2003.01.016
    1. Aravinthan A., Kim J. H., Antonisamy P., Kang C. W., Choi J., Kim N. S., et al. (2015). Ginseng total saponin attenuates myocardial injury via anti-oxidative and anti-inflammatory properties. J. Ginseng Res. 39 (3), 206–212. 10.1016/j.jgr.2014.12.001
    1. Bai Y. R., Wang R. Y. (2011). Observation on the curative effect of Shensong Yangxin Capsule in the treatment of arrhythmia. J. Cardiovasc. Cerebrovasc. Dis. Integr. Traditional Chin. West. Med. 9 (10), 1170–1171. 10.3969/j.issn.1672-1349.2011.10.011
    1. Bai C. X., Sunami A., Namiki T., Sawanobori T., Furukawa T. (2003). Electrophysiological effects of ginseng and ginsenoside Re in Guinea pig ventricular myocytes. Eur. J. Pharmacol. 476 (1-2), 35–44. 10.1016/s0014-2999(03)02174-5
    1. Bai C. X., Takahashi K., Masumiya H., Sawanobori T., Furukawa T. (2004). Nitric oxide-dependent modulation of the delayed rectifier K+ current and the L-type Ca2+ current by ginsenoside Re, an ingredient of Panax ginseng, in Guinea-pig cardiomyocytes. Br. J. Pharmacol. 142 (3), 567–575. 10.1038/sj.bjp.0705814
    1. Borén J., Chapman M. J., Krauss R. M., Packard C. J., Bentzon J. F., Binder C. J., et al. (2020). Low-density lipoproteins cause atherosclerotic cardiovascular disease: Pathophysiological, genetic, and therapeutic insights: A consensus statement from the European atherosclerosis society consensus panel. Eur. Heart J. 41 (24), 2313–2330. 10.1093/eurheartj/ehz962
    1. Cao C. H., Xie F. (2010). Clinical observation of Yixinshu capsule in treating 102 cases of coronary heart disease and angina pectoris. J. Cardiovasc. Cerebrovasc. Dis. Integr. Traditional Chin. West. Med. 8 (2), 136–137. 10.3969/j.issn.1672-1349.2010.02.005
    1. Cao Z., Zhang Y. D., Xu Y. H. (2012). New progress in research on active ingredients and pharmacological effects of ginseng. Ginseng Res. 24 (2), 39–43. 10.3969/j.issn.1671-1521.2012.02.014
    1. Cao X. J. (2009). Clinical observation of Yixinshu capsule in treating 100 cases of coronary heart disease and angina pectoris. Eval. Analysis Drugs Chin. Hosp. 9 (7), 536–538. 10.14009/j.issn.1672-2124.2009.07.003
    1. Chai H., Zhou W., Lin P., Lumsden A., Yao Q., Chen C. (2005). Ginsenosides block HIV protease inhibitor ritonavir-induced vascular dysfunction of porcine coronary arteries. Am. J. Physiol. Heart Circ. Physiol. 288 (6), H2965–H2971. 10.1152/ajpheart.01271.2004
    1. Chen F., Huang G. (2019). Antioxidant activity of polysaccharides from different sources of ginseng. Int. J. Biol. Macromol. 125, 906–908. 10.1016/j.ijbiomac.2018.12.134
    1. Chen C. X., Zhang H. Y. (2009). Protective effect of ginsenoside Re on isoproterenol-induced triggered ventricular arrhythmia in rabbits. Zhongguo Dang Dai Er Ke Za Zhi 11 (5), 384–388.
    1. Chen X. D., Zhou J. (2015). Combined application of Qili Qiangxin Capsule and trimetazidine in patients with ischemic cardiomyopathy and heart failure. Chin. J. Exp. Prescr. 21 (19), 171–175. 10.13422/j.cnki.syfjx.2015190171
    1. Chen Y. J., Huang Z., Li N. P. (1982). Study on volatile oil of ginseng. China J. Chin. Materia Medica 7 (4).
    1. Chen Y. J., Dou D. Q., Zhao C. J. (2002). Research on new components, new activities and quality standardization of ginseng. Ginseng Res. 14 (1), 2–19. 10.3969/j.issn.1671-1521.2002.01.001
    1. Chen L. X., Kuang J. B., Deng Y. (2006). Clinical observation of Shensong Yangxin capsule in the treatment of arrhythmia. Int. Med. Health Her. 12 (14), 103–104. 10.3760/cma.j.issn.1007-1245.2006.14.053
    1. Chen H., Yin J., Deng Y., Yang M., Xu L., Teng F., et al. (2012). The protective effects of ginsenoside Rg1 against hypertension target-organ damage in spontaneously hypertensive rats. BMC Complement. Altern. Med. 12, 53. 10.1186/1472-6882-12-53
    1. Chen X., Wang Q., Shao M., Ma L., Guo D., Wu Y., et al. (2019). Ginsenoside Rb3 regulates energy metabolism and apoptosis in cardiomyocytes via activating PPARα pathway. Biomed. Pharmacother. 120, 109487. 10.1016/j.biopha.2019.109487
    1. Chen X., Wang Y. F., Zhang Z. X. (2020). Current status and treatment progress of arrhythmia in China. Chin. J. Res. Hosp. 7 (1), 75198–78201. 10.19450/j.cnki.jcrh.2020.01.016
    1. Chen X. Z., Wang J., Fu D. (2022). Research progress of ginseng active ingredients and preparations in cardiovascular diseases. Clin. Res. TCM 14 (09), 140–144. 10.3969/j.issn.1674-7860.2022.09.049
    1. Chen S. W. (2015). Preclinical study of the new drug "Compound Ginseng Volatile Oil Spray" for the treatment of coronary heart disease and angina pectoris. Jilin Province: Changchun University of Traditional Chinese Medicine.
    1. China Cardiovascular Health and Disease Report Writing Group (2021). China cardiovascular health and disease report 2020 outline. Chin. J. Circulation 36 (6), 521–545. 10.3969/j.issn.1000-3614.2021.06.001
    1. Chinese Cardiovascular Health and Disease Report Writing Group (2022). Overview of China cardiovascular health and disease report 2021. Chin. J. Circulation 37 (6), 553–578. 10.3969/j.issn.1000-3614.2022.06.001
    1. Choi S. H., Lee J. H., Pyo M. K., Lee B. H., Shin T. J., Hwang S. H., et al. (2009). Mutations Leu427, Asn428, and Leu431 residues within transmembrane domain-I-segment 6 attenuate ginsenoside-mediated L-type Ca(2+) channel current inhibitions. Biol. Pharm. Bull. 32 (7), 1224–1230. 10.1248/bpb.32.1224
    1. Cholesterol Treatment Trialists' (CTT) Collaboration O'Connell R., Voysey M., Emberson J., Blackwell L., Mihaylova B., Simes J., et al. (2015). Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174, 000 participants in 27 randomised trials. Lancet 385 (9976), 1397–1405. 10.1016/S0140-6736(14)61368-4
    1. Chu S. F., Zhang J. T. (2009). New achievements in ginseng research and its future prospects. Chin. J. Integr. Med. 15 (6), 403–408. 10.1007/s11655-009-0403-6
    1. Dai Y. R., Yin Y. (1987). Study on the inhibition effect of B-type monoamine oxidase in traditional Chinese medicine. Chin. J. Geriatrics 06 (1), 27–30. 10.3760/cma.j.issn.0254-9026.1987.01.114
    1. Davies M. J., Gordon J. L., Gearing A. J., Pigott R., Woolf N., Katz D., et al. (1993). The expression of the adhesion molecules ICAM-1, VCAM-1, PECAM, and E-selectin in human atherosclerosis. J. Pathol. 171 (3), 223–229. 10.1002/path.1711710311
    1. Deng Y. F., Liu J. L. (2013). Effects of Qishen Capsules on hs-CRP and BNP in patients with angina pectoris. China Pract. Med. 8 (25), 150–151. 10.3969/j.issn.1673-7555.2013.25.113
    1. Deng J., Liu Y., Duan Z., Zhu C., Hui J., Mi Y., et al. (2017). Protopanaxadiol and protopanaxatriol-type saponins ameliorate glucose and lipid metabolism in type 2 diabetes mellitus in high-fat diet/streptozocin-induced mice. Front. Pharmacol. 8, 506. 10.3389/fphar.2017.00506
    1. Dong G., Chen T., Ren X., Zhang Z., Huang W., Liu L., et al. (2016). Rg1 prevents myocardial hypoxia/reoxygenation injury by regulating mitochondrial dynamics imbalance via modulation of glutamate dehydrogenase and mitofusin 2. Mitochondrion 26, 7–18. 10.1016/j.mito.2015.11.003
    1. Duan L., Xiong X., Hu J., Liu Y., Li J., Wang J. (2017). Panax notoginseng saponins for treating coronary artery disease: A functional and mechanistic overview. Front. Pharmacol. 8, 702. 10.3389/fphar.2017.00702
    1. Ezzati M., Lopez A. D., Rodgers A., Vander Hoorn S., Murray C. J. Comparative Risk Assessment Collaborating Group (2002). Selected major risk factors and global and regional burden of disease. Lancet 360 (9343), 1347–1360. 10.1016/S0140-6736(02)11403-6
    1. Furukawa T., Bai C. X., Kaihara A., Ozaki E., Kawano T., Nakaya Y., et al. (2006). Ginsenoside Re, a main phytosterol of Panax ginseng, activates cardiac potassium channels via a nongenomic pathway of sex hormones. Mol. Pharmacol. 70 (6), 1916–1924. 10.1124/mol.106.028134
    1. Gao Y., Zhu P., Xu S. F., Li Y. Q., Deng J., Yang D. L. (2019). Ginsenoside Re inhibits PDGF-BB-induced VSMC proliferation via the eNOS/NO/cGMP pathway. Biomed. Pharmacother. 115, 108934. 10.1016/j.biopha.2019.108934
    1. Gou D., Pei X., Wang J., Wang Y., Hu C., Song C., et al. (2020). Antiarrhythmic effects of ginsenoside Rg2 on calcium chloride-induced arrhythmias without oral toxicity. J. Ginseng Res. 44 (5), 717–724. 10.1016/j.jgr.2019.06.005
    1. Guo J., Gan X. T., Haist J. V., Rajapurohitam V., Zeidan A., Faruq N. S., et al. (2011). Ginseng inhibits cardiomyocyte hypertrophy and heart failure via NHE-1 inhibition and attenuation of calcineurin activation. Circ. Heart Fail. 4 (1), 79–88. 10.1161/CIRCHEARTFAILURE.110.957969
    1. Guo M., Guo G., Xiao J., Sheng X., Zhang X., Tie Y., et al. (2018a). Ginsenoside Rg3 stereoisomers differentially inhibit vascular smooth muscle cell proliferation and migration in diabetic atherosclerosis. J. Cell. Mol. Med. 22 (6), 3202–3214. 10.1111/jcmm.13601
    1. Guo M., Xiao J., Sheng X., Zhang X., Tie Y., Wang L., et al. (2018b). Ginsenoside Rg3 mitigates atherosclerosis progression in diabetic apoE-/- mice by skewing macrophages to the M2 phenotype. Front. Pharmacol. 9, 464. 10.3389/fphar.2018.00464
    1. Gutiérrez E., Flammer A. J., Lerman L. O., Elízaga J., Lerman A., Fernández-Avilés F. (2013). Endothelial dysfunction over the course of coronary artery disease. Eur. Heart J. 34 (41), 3175–3181. 10.1093/eurheartj/eht351
    1. Hao P., Jiang F., Cheng J., Ma L., Zhang Y., Zhao Y. (2017). Traditional Chinese medicine for cardiovascular disease: Evidence and potential mechanisms. J. Am. Coll. Cardiol. 69 (24), 2952–2966. 10.1016/j.jacc.2017.04.041
    1. Heart Failure Group of Cardiology (2018). Chinese guidelines for the diagnosis and treatment of heart failure 2018. Chin. J. Cardiovasc. Dis. 46, 760–789. 10.3760/cma.j.issn.0253-3758.2018.10.004
    1. Hernández-García D., Granado-Serrano A. B., Martín-Gari M., Naudí A., Serrano J. C. (2019). Efficacy of Panax ginseng supplementation on blood lipid profile. A meta-analysis and systematic review of clinical randomized trials. J. Ethnopharmacol. 243, 112090. 10.1016/j.jep.2019.112090
    1. Hien T. T., Kim N. D., Kim H. S., Kang K. W. (2010). Ginsenoside Rg3 inhibits tumor necrosis factor-alpha-induced expression of cell adhesion molecules in human endothelial cells. Pharmazie 65 (9), 699–701.
    1. Huang B. (2010). Effects of Qili Qiangxin Capsule on cardiac function and plasma brain natriuretic peptide level in patients with chronic systolic heart failure. Chin. J. Exp. Prescr. 16 (16), 191–193. 10.3969/j.issn.1005-9903.2010.16.057
    1. Im D. S. (2020). Pro-resolving effect of ginsenosides as an anti-inflammatory mechanism of panax ginseng. Biomolecules 10 (3), 444. 10.3390/biom10030444
    1. Irfan M., Kim M., Rhee M. H. (2020). Anti-platelet role of Korean ginseng and ginsenosides in cardiovascular diseases. J. Ginseng Res. 44 (1), 24–32. 10.1016/j.jgr.2019.05.005
    1. Janetzky K., Morreale A. P. (1997). Probable interaction between warfarin and ginseng. Am. J. Health. Syst. Pharm. 54 (6), 692–693. 10.1093/ajhp/54.6.692
    1. Jeon B. H., Kim C. S., Kim H. S., Park J. B., Nam K. Y., Chang S. J. (2000). Effect of Korean red ginseng on blood pressure and nitric oxide production. Acta Pharmacol. Sin. 21 (12), 1095–1100.
    1. Jeong D., Irfan M., Kim S. D., Kim S., Oh J. H., Park C. K., et al. (2017). Ginsenoside Rg3-enriched red ginseng extract inhibits platelet activation and in vivo thrombus formation. J. Ginseng Res. 41 (4), 548–555. 10.1016/j.jgr.2016.11.003
    1. Jia Y., Zhang S., Huang F., Leung S. W. (2012). Could ginseng-based medicines be better than nitrates in treating ischemic heart disease? A systematic review and meta-analysis of randomized controlled trials. Complement. Ther. Med. 20 (3), 155–166. 10.1016/j.ctim.2011.12.002
    1. Jiang Q. S., Huang X. N., Dai Z. K., Yang G. Z., Zhou Q. X., Shi J. S., et al. (2007). Inhibitory effect of ginsenoside Rb1 on cardiac hypertrophy induced by monocrotaline in rat. J. Ethnopharmacol. 111 (3), 567–572. 10.1016/j.jep.2007.01.006
    1. Jiao H. C., Ding S. W. (2015). “Clinical and basic research of Chinese medicine Xinsuning capsule in the treatment of premature beat,” in The Proceedings of the 2015 Academic Conference of the Heart Disease Branch of the Chinese Society of Traditional Chinese Medicine.
    1. Jin Z. Q., Liu C. M. (1994). Effect of ginsenoside Re on the electrophysiological activity of the heart. Planta Med. 60 (2), 192–193. 10.1055/s-2006-959452
    1. Jin C., Zhang S. Z. (1995). Rise and prospect of glycobiology and glycoengineering. Adv. Bioeng. (3), 12–17. 10.13523/j.cb.19950306
    1. Kaku T., Miyata T., Uruno T., Sako I., Kinoshita A. (1975). Chemico-pharmacological studies on saponins of Panax ginseng C. A. Meyer. II. Pharmacological part. Arzneimittelforschung. 25 (4), 539–547.
    1. Kannel W. B. (2000). Incidence and epidemiology of heart failure. Heart fail. Rev. 5 (2), 167–173. 10.1023/A:1009884820941
    1. Kim S. H., Park K. S. (2003). Effects of Panax ginseng extract on lipid metabolism in humans. Pharmacol. Res. 48 (5), 511–513. 10.1016/s1043-6618(03)00189-0
    1. Konukoglu D., Uzun H. (2017). Endothelial dysfunction and hypertension. Adv. Exp. Med. Biol. 956, 511–540. 10.1007/5584_2016_90
    1. Kuriachan V. P., Sumner G. L., Mitchell L. B. (2015). Sudden cardiac death. Curr. Probl. Cardiol. 40 (4), 133–200. 10.1016/j.cpcardiol.2015.01.002
    1. Kwon H. W. (2018a). Inhibitory effect of 20(S)-Ginsenoside Rg3 on human platelet aggregation and intracellular Ca2+ levels via cyclic adenosine monophosphate dependent manner. Prev. Nutr. Food Sci. 23 (4), 317–325. 10.3746/pnf.2018.23.4.317
    1. Kwon H. W . (2018b). 20(S)-ginsenoside Rg3 inhibits glycoprotein IIb/IIIa activation in human platelets. J. Appl. Biol. Chem. 61 (3), 257–265. 10.3839/jabc.2018.037
    1. Lee W. M., Kim S. D., Park M. H., Cho J. Y., Park H. J., Seo G. S., et al. (2008). Inhibitory mechanisms of dihydroginsenoside Rg3 in platelet aggregation: Critical roles of ERK2 and cAMP. J. Pharm. Pharmacol. 60 (11), 1531–1536. 10.1211/jpp/60.11.0015
    1. Lee K. H., Bae I. Y., Park S. I., Park J. D., Lee H. G. (2016). Antihypertensive effect of Korean Red Ginseng by enrichment of ginsenoside Rg3 and arginine-fructose. J. Ginseng Res. 40 (3), 237–244. 10.1016/j.jgr.2015.08.002
    1. Lee J. W., Choi B. R., Kim Y. C., Choi D. J., Lee Y. S., Kim G. S., et al. (2017a). Comprehensive profiling and quantification of ginsenosides in the root, stem, leaf, and berry of panax ginseng by UPLC-QTOF/MS. Molecules 22 (12), 2147. 10.3390/molecules22122147
    1. Lee H. W., Lim H. J., Jun J. H., Choi J., Lee M. S. (2017b). Ginseng for treating hypertension: A systematic review and meta-analysis of double blind, randomized, placebo-controlled trials. Curr. Vasc. Pharmacol. 15 (6), 549–556. 10.2174/1570161115666170713092701
    1. Li P., Liu Z. X. (2006). Effects of ginsenoside Rb1 on ventricular remodeling in rats with acute myocardial infarction. J. Pract. Cardiovasc. Cerebrovasc. Dis. 14 (2), 118–121. 10.3969/j.issn.1008-5971.2006.02.017
    1. Li C. Y., Shi Z. X. (2013). Clinical research progress of Yixinshu capsule in the treatment of coronary heart disease angina pectoris. J. Cardiovasc. Cerebrovasc. Dis. 11 (3), 351–352. 10.3969/j.issn.1672-1349.2013.03.052
    1. Li X. G., Teng F. T. (1978). Study on the active ingredients of ginseng—Extraction, separation and identification of ginsenosides and their sapogenins. J. Res. Chin. Pat. Med. (03), 1.
    1. Li R. Q., Zhang Y. S. (1984). Purification and characterization of Panax ginseng C. A. Mey pectin. Chin. J. Pharm. 19 (10), 764–768. 10.16438/j.0513-4870.1984.10.009
    1. Li R. Q., Zhang Y. Y. (1986). Structural studies of Panax ginseng C. A. Mey pectin. Chin. J. Pharm. 21 (12), 912–916. 10.16438/j.0513-4870.1986.12.006
    1. Li F. X., Zhang C. F. (2015). Clinical study of Xinsuning capsule in the treatment of paroxysmal atrial fibrillation. Front. Med. 55 (26), 95–97. 10.3969/j.issn.2095-1752.2015.26.077
    1. Li N., Wu X. F., Ma K. J. (2007). Effects of Shensong Yangxin Capsules on potassium channels in ventricular myocytes. J. Difficult Dis. 6 (3), 133–137. 10.3969/j.issn.1671-6450.2007.03.002
    1. Li Y. Q., Wen H. J., Liu W. M. (2010). Effects of Shenshao Capsule on myocardial remodeling in atherosclerotic rats. Shandong Med. 50 (4), 21–23. 10.3969/j.issn.1002-266X.2010.04.008
    1. Li J., Shao Z. H., Xie J. T., Wang C. Z., Ramachandran S., Yin J. J., et al. (2012). The effects of ginsenoside Rb1 on JNK in oxidative injury in cardiomyocytes. Arch. Pharm. Res. 35 (7), 1259–1267. 10.1007/s12272-012-0717-3
    1. Li Q., Xiang Y., Chen Y., Tang Y., Zhang Y. (2017). Ginsenoside Rg1 protects cardiomyocytes against hypoxia/reoxygenation injury via activation of Nrf2/HO-1 signaling and inhibition of JNK. Cell. Physiol. biochem. 44 (1), 21–37. 10.1159/000484578
    1. Li F., Long Y., Ma H., Qiang T., Zhang G., Shen Y. (2022). Promoting the reduction of CO2 to formate and formaldehyde via gas-liquid interface dielectric barrier discharge using a Zn0.5Cd0.5S/CoP/multiwalled carbon nanotubes catalyst. J. Colloid Interface Sci. 46 (6), 880–891. 10.1016/j.jcis.2022.04.125
    1. Li T. C. (2015). Application of Shenshao Capsule in the treatment of unstable angina pectoris. Shandong Med. 55 (38), 34–35. 10.3969/j.issn.1002-266X.2015.38.012
    1. Liao D. N., Yang Z. J. (2008). The mechanism of antiarrhythmic drug-induced arrhythmia. Intern. Med. Theory Pract. 3 (4), 232–234. 10.16138/j.1673-6087.2008.04.006
    1. Lin G. W., Wang J. Y., Ge J. B. (2017). Practical internal medicine. J. Sci. Technol. (12), 2. 10.16510/j.cnki.kjycb.2017.12.001
    1. Liu J. X., Ma X. B., Wang Y. H. (2007). Effects of Qili Qiangxin Capsule on cardiac function in dogs with experimental heart failure. J. Difficult Difficult Dis. 6 (3), 141–143. 10.3969/j.issn.1671-6450.2007.03.004
    1. Liu J. J., Li S. G., Deng J. J., Ye M., Zhang D., Peng Y., et al. (2016). Effects of ginsenoside Rg3 on vascular structure and function in aged rats. J. Clin. Cardiovasc. Dis. 32 (11), 1154–1158. 10.13201/j.issn.1001-1439.2016.11.020
    1. Liu Z., Song L., Zhang P., Cao Z., Hao J., Tian Y., et al. (2019). Ginsenoside Rb1 exerts antiarrhythmic effects by inhibiting INa and ICaL in rabbit ventricular myocytes. Sci. Rep. 9 (1), 20425. 10.1038/s41598-019-57010-9
    1. Liu X., Jiang Y., Fu W., Yu X., Sui D. (2020a). Combination of the ginsenosides Rb3 and Rb2 exerts protective effects against myocardial ischemia reperfusion injury in rats. Int. J. Mol. Med. 45 (2), 519–531. 10.3892/ijmm.2019.4414
    1. Liu L. S., Yue J. B., Ding X. (2020b). Clinical study of Shenshao Capsule combined with verapamil in the treatment of unstable angina pectoris. Mod. Med. Clin. 35 (1), 83–87. 10.7501/j.issn.1674-5515.2020.01.018
    1. Liu K. (2021). Advances in diagnosis and treatment of arrhythmia. Chin. J. Prescr. Drugs 19 (9), 23–26. 10.3969/j.issn.1671-945X.2021.09.010
    1. Lo S. H., Hsu C. T., Niu H. S., Niu C. S., Cheng J. T., Chen Z. C. (2017). Ginsenoside Rh2 improves cardiac fibrosis via pparδ-STAT3 signaling in type 1-like diabetic rats. Int. J. Mol. Sci. 18 (7), 1364. 10.3390/ijms18071364
    1. Lu W. J., Zhou J., Ma H. Y. (2012). Effects of astragaloside IV, total ginseng saponins and total American ginseng saponins on arrhythmia in mice induced by toadstool. J. Nanjing Univ. Traditional Chin. Med. 28 (01), 61–64. 10.14148/j.issn.1672-0482.2012.01.020
    1. Lu S., Luo Y., Zhou P., Yang K., Sun G., Sun X. (2019). Ginsenoside compound K protects human umbilical vein endothelial cells against oxidized low-density lipoprotein-induced injury via inhibition of nuclear factor-κB, p38, and JNK MAPK pathways. J. Ginseng Res. 43 (1), 95–104. 10.1016/j.jgr.2017.09.004
    1. Luo X. P., Li Y., Fan W. H. (1998). Experimental study on the effect of Shexiang Baoxin pills on reducing the damage of arterial wall caused by hyperlipidemia. China J. Integr. Traditional Chin. West. Med. (8). 10.3321/j.issn:1003-5370.1998.08.012
    1. Nagar H., Choi S., Jung S. B., Jeon B. H., Kim C. S. (2016). Rg3-enriched Korean Red Ginseng enhances blood pressure stability in spontaneously hypertensive rats. Integr. Med. Res. 5 (3), 223–229. 10.1016/j.imr.2016.05.006
    1. Nanao-Hamai M., Son B. K., Komuro A., Asari Y., Hashizume T., Takayama K. I., et al. (2019). Ginsenoside Rb1 inhibits vascular calcification as a selective androgen receptor modulator. Eur. J. Pharmacol. 859, 172546. 10.1016/j.ejphar.2019.172546
    1. Qin N., Gong Q. H., Wei L. W., Wu Q., Huang X. N. (2008). Total ginsenosides inhibit the right ventricular hypertrophy induced by monocrotaline in rats. Biol. Pharm. Bull. 31 (8), 1530–1535. 10.1248/bpb.31.1530
    1. Rezende P. C., Ribas F. F., Serrano C. V., Jr, Hueb W. (2019). Clinical significance of chronic myocardial ischemia in coronary artery disease patients. J. Thorac. Dis. 11 (3), 1005–1015. 10.21037/jtd.2019.02.85
    1. Ryoo S., Berkowitz D. E., Lim H. K. (2011). Endothelial arginase II and atherosclerosis. Korean J. Anesthesiol. 61 (1), 3–11. 10.4097/kjae.2011.61.1.3
    1. Ryu S. J., Chien Y. Y. (1995). Ginseng-associated cerebral arteritis. Neurology 45 (4), 829–830. 10.1212/wnl.45.4.829
    1. Shang J. H. (2003). Clinical observation on treating angina pectoris with Qishen capsules. Chin. Pat. Med. 25 (4), 303–304. 10.3969/j.issn.1001-1528.2003.04.014
    1. Shin W., Yoon J., Oh G. T., Ryoo S. (2013). Korean red ginseng inhibits arginase and contributes to endotheliumdependent vasorelaxation through endothelial nitric oxide synthase coupling. J. Ginseng Res. 37 (1), 64–73. 10.5142/jgr.2013.37.64
    1. Shin J. H., Kwon H. W., Cho H. J., Rhee M. H., Park H. J. (2016). Vasodilator-stimulated phosphoprotein-phosphorylation by ginsenoside Ro inhibits fibrinogen binding to αIIb/β3 in thrombin-induced human platelets. J. Ginseng Res. 40 (4), 359–365. 10.1016/j.jgr.2015.11.003
    1. Siegel R. K. (1979). Ginseng abuse syndrome. Problems with the panacea. JAMA 241 (15), 1614–1615. 10.1001/jama.1979.03290410046024
    1. Smolinske S. C. (1972). Dietary supplement-drug interactions. J. Am. Med. Womens Assoc. 54 (4), 191.
    1. Song X. L., Yang X. C., Lu N. (2022). A multicenter randomized controlled study of Xinsuning capsules in the treatment of phlegm-heat disturbed heart syndrome with premature ventricular contractions. China J. Integr. Med. 42 (4), 438–443. 10.7661/j.cjim.20220320.067
    1. Stöger J. L., Gijbels M. J., van der Velden S., Manca M., van der Loos C. M., Biessen E. A., et al. (2012). Distribution of macrophage polarization markers in human atherosclerosis. Atherosclerosis 225 (2), 461–468. 10.1016/j.atherosclerosis.2012.09.013
    1. Su P., Du S., Li H., Li Z., Xin W., Zhang W. (2016). Notoginsenoside R1 inhibits oxidized low-density lipoprotein induced inflammatory cytokines production in human endothelial EA.hy926 cells. Eur. J. Pharmacol. 770, 9–15. 10.1016/j.ejphar.2015.11.040
    1. Sun Y. X., Wang H. (1997). Application of variable temperature infrared spectroscopy in extraction of essential oil from ginseng. Synth. Chem. 005 (A10), 759.
    1. Sun X., Gao R. L., Lin X. J., Xu W. H., Chen X. H. (2013). Panax notoginseng saponins induced up-regulation, phosphorylation and binding activity of MEK, ERK, AKT, PI-3K protein kinases and GATA transcription factors in hematopoietic cells. Chin. J. Integr. Med. 19 (2), 112–118. 10.1007/s11655-012-1306-4
    1. Sun J., Yu X., Huangpu H., Yao F. (2019). Ginsenoside Rb3 protects cardiomyocytes against hypoxia/reoxygenation injury via activating the antioxidation signaling pathway of PERK/Nrf2/HMOX1. Biomed. Pharmacother. 109, 254–261. 10.1016/j.biopha.2018.09.002
    1. Takagi K., Saito H., Nabata H. (1972). Pharmacological studies of panax ginseng root: Estimation of pharmacological actions of panax ginseng root. Jpn. J. Pharmacol. 22 (2), 245–249. 10.1254/jjp.22.245
    1. Tao Y. J., Jiang B. H., Qiu H. (2009). Curative effect observation of Yixinshu capsule in the treatment of unstable angina pectoris. J. Cardiovasc. Cerebrovasc. Dis. Integr. Traditional Chin. West. Med. 7 (5), 596–597. 10.3969/j.issn.1672-1349.2009.05.046
    1. Teng C. M., Kuo S. C., Ko F. N., Lee J. C., Lee L. G., Chen S. C., et al. (1989). Antiplatelet actions of panaxynol and ginsenosides isolated from ginseng. Biochim. Biophys. Acta 990 (3), 315–320. 10.1016/s0304-4165(89)80051-0
    1. Tian Y. B., Zhao D. Q., Li X. Y. (2018). Ginseng polysaccharide protects cardiomyocytes from H2O2-induced oxidative stress injury by inhibiting ROS level and apoptosis. J. Central China Normal Univ. Nat. Sci. Ed. 52 (2), 240–247. 10.19603/j.cnki.1000-1190.2018.02.014
    1. Tsai C. C., Chan P., Chen L. J., Chang C. K., Liu Z., Lin J. W. (2014). Merit of ginseng in the treatment of heart failure in type 1-like diabetic rats. Biomed. Res. Int. 2014, 484161. 10.1155/2014/484161
    1. Virani S. S., Alonso A., Benjamin E. J., Bittencourt M. S., Callaway C. W., Carson A. P., et al. (2020). Heart disease and stroke statistics-2020 update: A report from the American heart association. Circulation 141 (9), e139–e596. 10.1161/CIR.0000000000000757
    1. Wan H. F., Ying J. N., Guan Y. (2020). Protective effect of ginseng polysaccharides on mitochondria in myocardial cells of rats with coronary heart disease. Mod. Food Sci. Technol. 36 (11), 2460–2528. 10.13982/j.mfst.1673-9078.2020.11.0510
    1. Wang G., Li J. P. (2012). Effects of Tongxinluo capsules on serum IL-18 and hs-CRP in elderly patients with coronary heart disease and angina pectoris. Guangdong Med. 33 (2), 276–278. 10.3969/j.issn.1001-9448.2012.02.053
    1. Wang C. H., Lu J. (2008). Xinsuning capsule in the treatment of 30 cases of viral myocarditis. Shaanxi Tradit. Chin. Med. 29 (10), 1362. 10.3969/j.issn.1000-7369.2008.10.068
    1. Wang H. L., Zhi J. C. (2016). Clinical observation of Yixinshu capsule combined with isosorbide dinitrate tablets in the treatment of angina pectoris. Medicine 000 (004), 285. 10.16138/j.1671-5837.2016.04.026
    1. Wang S. S., Li Y., Fan W. H. (2002). Angiogenesis-promoting effect of Shexiang Baoxin Pill on the heart of rats with experimental myocardial infarction. Chin. Pat. Med. 24 (6), 446–449. 10.3969/j.issn.1001-1528.2002.06.016
    1. Wang D. Y., Li Y., Fan W. H. (2004). Effects of Shexiang Baoxin Pill on infarct size and angiogenesis in rats with myocardial infarction. Chin. Pat. Med. 26 (11), 912–915. 10.3969/j.issn.1001-1528.2004.11.018
    1. Wang N. Y., Lu C. J., Chen X. H. (2005). Study on effect of ginsenoside Rg1 in promoting myocardiac vascular endothelial cell regeneration through induction on bone marrow stem cell's migration and differentiation in rabbits of myocardial infarction. China J. Integr. Traditional Chin. West. Med. 25 (10), 916–919. 10.3321/j.issn:1003-5370.2005.10.014
    1. Wang T. X., Yu X. F., Qu S. C., et al. (2008). Effect of ginseng Rb group saponins on ventricular remodeling in rats with stress-loaded myocardial hypertrophy and its mechanism of action. J. Lishizhen Med. Materia Medica Res. 19 (7), 1615–1617. 10.3969/j.issn.1008-0805.2008.07.032
    1. Wang X., Duan H. N., Hu J. (2012). Experimental study on the effect of Shensong Yangxin capsule on cardiac function and cardiac electrophysiology. Chin. J. Cardiac Arrhythmia 16 (6), 417–421. 10.3760/cma.j.issn.1007-6638.2012.06.004
    1. Wang Y., Dong J., Liu P., Lau C. W., Gao Z., Zhou D., et al. (2014). Ginsenoside Rb3 attenuates oxidative stress and preserves endothelial function in renal arteries from hypertensive rats. Br. J. Pharmacol. 171 (13), 3171–3181. 10.1111/bph.12660
    1. Wang Y., Hu Z., Sun B., Xu J., Jiang J., Luo M. (2015). Ginsenoside Rg3 attenuates myocardial ischemia/reperfusion injury via Akt/endothelial nitric oxide synthase signaling and the B-cell lymphoma/B-cell lymphoma-associated X protein pathway. Mol. Med. Rep. 11 (6), 4518–4524. 10.3892/mmr.2015.3336
    1. Wang Q. W., Yu X. F., Xu H. L., Zhao X. Z., Sui D. Y. (2019). Ginsenoside Re improves isoproterenol-induced myocardial fibrosis and heart failure in rats. Evid. Based Complement. Altern. Med. 2019, 3714508. 10.1155/2019/3714508
    1. Wang Y. J. (2010). Clinical study of Qishen capsule in the treatment of coronary heart disease and angina pectoris. Chin. J. Traditional Chin. Med. 25 (5), 939–940.
    1. World Health Statistics (2022). The global health observatory. Avaliable at: .
    1. Wu J. Z., Li X. G., Yang J. X. (1996). Comparative study on the volatile oil components of fresh ginseng in Hongshen. Strait Pharm. (1), 5–6.
    1. Wu X. L., Li J. B., Zhang Y. (2001). Clinical study of Tongxinluo capsule on blood lipid and blood viscosity. China J. Basic Med. Traditional Chin. Med. 7 (5), 32–33. 10.3969/j.issn.1006-3250.2001.05.015
    1. Wu Z. L., Xu D. L., Lin S. (2011). Effects of Qili Qiangxin Capsule on cardiac function and plasma vasopressin in rats with chronic heart failure. J. Difficult Difficult Dis. 10 (2), 120–122. 10.3969/j.issn.1671-6450.2011.02.020
    1. Xiao W. L., Dai H., Jiang Z. A. (2002). Study on the protective effect of Tongxinluo capsule on vascular endothelial cells in patients with unstable angina pectoris. Chin. J. Cardiovasc. Dis. 30 (5), 268. 10.3760/j:issn:0253-3758.2002.05.017
    1. Xu H., Ge Y. K., Deng T. L., (2005). Protective effect of ginsenoside Rb1 on H2O2-induced cardiomyocyte apoptosis in neonatal rats. Chin. Pharmacol. Bull. 21 (7), 803–806. 10.3321/j.issn:1001-1978.2005.07.009
    1. Xu Z. M., Li C. B., Liu Q. L., Li P., Yang H. (2018). Ginsenoside Rg1 prevents doxorubicin-induced cardiotoxicity through the inhibition of autophagy and endoplasmic reticulum stress in mice. Int. J. Mol. Sci. 19 (11), 3658. 10.3390/ijms19113658
    1. Yan J. C., Zhang H., Wei Y. D. (1994). Extraction and analysis of volatile oil from ginseng. J. Analysis Test. 13 (3), 5.
    1. Yang Q., Huang L. (2013). Observation on the efficacy of Qishen Capsules in the treatment of coronary heart disease angina pectoris. China Emerg. Med. 22 (9), 1602. 10.3969/j.issn.1004-745X.2013.09.070
    1. Yang P., Ling L., Sun W., Yang J., Zhang L., Chang G., et al. (2018). Ginsenoside Rg1 inhibits apoptosis by increasing autophagy via the AMPK/mTOR signaling in serum deprivation macrophages. Acta Biochim. Biophys. Sin. 50 (2), 144–155. 10.1093/abbs/gmx136
    1. Yang M. (2020). Clinical observation of Xinsuning capsule combined with Betaloc in the treatment of premature ventricular contractions. Guizhou Med. 44 (3), 425–427. 10.3969/j.issn.1000-744X.2020.03.033
    1. Yi X. Q., Li T., Wang J. R., Wong V. K., Luo P., Wong I. Y., et al. (2010). Total ginsenosides increase coronary perfusion flow in isolated rat hearts through activation of PI3K/Akt-eNOS signaling. Phytomedicine 17 (13), 1006–1015. 10.1016/j.phymed.2010.06.012
    1. Yi D. L. (2013). Analysis of rational use of cardiovascular drugs in the elderly. Chin. J. Health Nutr. 23 (3), 1376. 10.3969/j.issn.1004-7484(s).2013.03.436
    1. You S. J., Yang Y. J., Chen K. J. (2004). Efficacy and safety of Tongxinluo capsule after revascularization in acute myocardial infarction. J. Difficult Difficult Dis. 3 (4), 193–196. 10.3969/j.issn.1671-6450.2004.04.001
    1. You J. S., Huang H. F., Chang Y. L. (2005). Panax ginseng reduces adriamycin-induced heart failure in rats. Phytother. Res. 19 (12), 1018–1022. 10.1002/ptr.1778
    1. Yuan J., Guo W., Yang B., Liu P., Wang Q., Yuan H. (1997). 116 cases of coronary angina pectoris treated with powder composed of radix ginseng, radix notoginseng and succinum. J. Tradit. Chin. Med. 17 (1), 14–17.
    1. Yuan S. W. (2000). Observation on 60 cases of tachyarrhythmia in xinsuning capsule. J. Shandong Univ. Traditional Chin. Med. 24 (4), 4. 10.3969/j.issn.1007-659X.2000.04.027
    1. Zhang W., Ding J. X. (2021). Clinical effect of Shenshao Capsule in the treatment of coronary heart disease angina pectoris. J. Clin. Ration. Med. 14 (35), 38–39. 10.15887/j.cnki.13-1389/r.2021.35.013
    1. Zhang R., Liu Y. F. (2009). Effects of ginsenoside Rg1 on angiogenesis and cardiac function after acute myocardial infarction in rats. Chongqing Med. Sci. 38 (7), 805–807. 10.3969/j.issn.1671-8348.2009.07.026
    1. Zhang Y. L., Zhu X. M. (2011). Clinical observation of Yixinshu Capsule in the treatment of diastolic heart failure. J. Cardiovasc. Cerebrovasc. Dis. Integr. Traditional Chin. West. Med. 9 (3), 287–289. 10.3969/j.issn.1672-1349.2011.03.015
    1. Zhang Y. S., Li R. Q., Wang Y. W. (1982). Study on ginseng polysaccharides (I). J. Northeast Normal Univ. Nat. Sci. Ed. 14 (02), 100–107. 10.16163/j.cnki.22-1123/n.1982.02.014
    1. Zhang H. G., Yan J. C., Wu G. X. (1994). Study on fatty acid components in ginseng of Changbai. J. Bethune Med. Univ. 20 (4), 365. 10.13481/j.1671-587x.1994.04.027
    1. Zhang X. M., Qu S. C., Sui D. Y., Yu X. F., Lv Z. Z. (2004). Effects of ginsenoside-Rb on blood lipid metabolism and anti-oxidation in hyperlipidemia rats. Zhongguo Zhong Yao Za Zhi 29 (11), 1085–1088. 10.3321/j.issn:1001-5302.2004.11.019
    1. Zhang Y. G., Zhang H. G., Zhang G. Y., Fan J. S., Li X. H., Liu Y. H., et al. (2008). Panax notoginseng saponins attenuate atherosclerosis in rats by regulating the blood lipid profile and an anti-inflammatory action. Clin. Exp. Pharmacol. Physiol. 35 (10), 1238–1244. 10.1111/j.1440-1681.2008.04997.x
    1. Zhang Z. L., Fan Y., Liu M. L. (2012). Ginsenoside Rg1 inhibits autophagy in H9c2 cardiomyocytes exposed to hypoxia/reoxygenation. Mol. Cell. Biochem. 365 (1-2), 243–250. 10.1007/s11010-012-1265-3
    1. Zhang Y. J., Zhang X. L., Li M. H., Iqbal J., Bourantas C. V., Li J. J., et al. (2013a). The ginsenoside Rg1 prevents transverse aortic constriction-induced left ventricular hypertrophy and cardiac dysfunction by inhibiting fibrosis and enhancing angiogenesis. J. Cardiovasc. Pharmacol. 62 (1), 50–57. 10.1097/FJC.0b013e31828f8d45
    1. Zhang D. L., Liang L. J., Zhang J. (2013b). Effects of ginseng polysaccharide on myocardial hypertrophy and myocardial energy metabolism in rats with abdominal aortic constriction. China Mod. Appl. Pharm. 30 (6), 571–575. 10.13748/j.cnki.issn1007-7693.2013.06.009
    1. Zhang J. F., Tang S. W., Wang H. T. (2013c). Effects of Qili Qiangxin Capsule on endothelial injury and energy metabolism in rats with pressure overload heart failure. J. Traditional Chin. Med. 54 (14), 5.
    1. Zhang Y. S., Chen X., Li Y. (2014). Research progress on the correlation between mitochondrial DNA mutations and essential hypertension. Chin. J. Multiple Organ Dis. Aged (10), 781–787. 10.3724/SP.J.1264.2014.000181
    1. Zhang L. P., Jiang Y. C., Yu X. F., Xu H. L., Li M., Zhao X. Z., et al. (2016). Ginsenoside Rg3 improves cardiac function after myocardial ischemia/reperfusion via attenuating apoptosis and inflammation. Evid. Based Complement. Altern. Med. 2016, 6967853. 10.1155/2016/6967853
    1. Zhang X., Liu M. H., Qiao L., Zhang X. Y., Liu X. L., Dong M., et al. (2018). Ginsenoside Rb1 enhances atherosclerotic plaque stability by skewing macrophages to the M2 phenotype. J. Cell Mol. Med. 22 (1), 409–416. 10.1111/jcmm.13329
    1. Zhang N., An X., Lang P., Wang F., Xie Y. (2019). Ginsenoside Rd contributes the attenuation of cardiac hypertrophy in vivo and in vitro . Biomed. Pharmacother. 109, 1016–1023. 10.1016/j.biopha.2018.10.081
    1. Zhang J., Luo D., Li F., Li Z., Gao X., Qiao J., et al. (2021). Ginsenoside Rg3 alleviates antithyroid cancer drug vandetanib-induced QT interval prolongation. Oxid. Med. Cell Longev. 2021, 3520034. 10.1155/2021/3520034
    1. Zhang Hj. (2011). Research progress of traditional Chinese and Western medicine on the pathogenesis of essential hypertension. Mod. J. Integr. Traditional Chin. West. Med. 20 (19), 2465–2467. 10.3969/j.issn.1008-8849.2011.19.087
    1. Zhang Y. (2016). Anti-myocardial ischemia mechanism of compound ginseng volatile oil aerosol and its effect on hemorheology. Jilin: Changchun University of Traditional Chinese Medicine.
    1. Zhao M. Z., Gao C. M., Zhang Y. Y. (2000). Experimental study on the protective effect of Tongxinluo capsule on experimental myocardial ischemia-reperfusion injury. China J. Basic Med. 6 (1), 36–38. 10.3969/j.issn.1006-3250.2000.01.013
    1. Zheng Q., Bao X. Y., Zhu P. C., Tong Q., Zheng G. Q., Wang Y. (2017a). Ginsenoside Rb1 for myocardial ischemia/reperfusion injury: Preclinical evidence and possible mechanisms. Oxid. Med. Cell. Longev. 2017, 6313625. 10.1155/2017/6313625
    1. Zheng X., Wang S., Zou X., Jing Y., Yang R., Li S., et al. (2017b). Ginsenoside Rb1 improves cardiac function and remodeling in heart failure. Exp. Anim. 66 (3), 217–228. 10.1538/expanim.16-0121
    1. Zhou W., Chai H., Lin P. H., Lumsden A. B., Yao Q., Chen C. (2005). Ginsenoside Rb1 blocks homocysteine-induced endothelial dysfunction in porcine coronary arteries. J. Vasc. Surg. 41 (5), 861–868. 10.1016/j.jvs.2005.01.054
    1. Zhou H., Hou S. Z., Luo P., Zeng B., Wang J. R., Wong Y. F., et al. (2011). Ginseng protects rodent hearts from acute myocardial ischemia-reperfusion injury through GR/ER-activated RISK pathway in an endothelial NOS-dependent mechanism. J. Ethnopharmacol. 135 (2), 287–298. 10.1016/j.jep.2011.03.015
    1. Zhou Q., Jiang L., Xu C., Luo D., Zeng C., Liu P., et al. (2014). Ginsenoside Rg1 inhibits platelet activation and arterial thrombosis. Thromb. Res. 133 (1), 57–65. 10.1016/j.thromres.2013.10.032
    1. Zhou S. S., Wang Y. Y., Liu D. (2015). Optimization of ultrasonic-assisted extraction of polysaccharide from ginseng flowers and its antioxidant activity. Food Sci. 36 (6), 76–81. 10.7506/spkx1002-6630-201506014
    1. Zhou P., Lu S., Luo Y., Wang S., Yang K., Zhai Y., et al. (2017). Attenuation of TNF-α-Induced inflammatory injury in endothelial cells by ginsenoside Rb1 via inhibiting NF-κB, JNK and p38 signaling pathways. Front. Pharmacol. 8, 464. 10.3389/fphar.2017.00464
    1. Zhou P., Lu S., Luo Y., Wang S., Yang K., Zhai Y., et al. (2017). Attenuation of TNF-α-Induced inflammatory injury in endothelial cells by ginsenoside Rb1 via inhibiting NF-κB, JNK and p38 signaling pathways. Front. Pharmacol. 8, 464. 10.3389/fphar.2017.00464
    1. Zhou P., Xie W., Luo Y., Lu S., Dai Z., Wang R., et al. (2018). Inhibitory effects of ginsenoside Rb1 on early atherosclerosis in ApoE-/- mice via inhibition of apoptosis and enhancing autophagy. Molecules 23 (11), 2912. 10.3390/molecules23112912
    1. Zhou P., Xie W., Sun Y., Dai Z., Li G., Sun G., et al. (2019). Ginsenoside Rb1 and mitochondria: A short review of the literature. Mol. Cell ProbesMol Cell Probes. 4354, 1101626–1101635. 10.1016/j.mcp.2018.12.001
    1. Zhu H., Luo X. P., Wang L. J. (2010). Evaluation on clinical effect of long-term shexiang baoxin pill administration for treatment of coronary heart disease. China J. Integr. Traditional Chin. West. Med. 30 (5), 474–477.
    1. Zuo X. (2021). Anti-inflammatory activity of ginseng volatile oil. Changchun, China: Jilin University.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa